HSIL Limited Stock Price Today (NSE: HSIL)
Fundamental Score
HSIL Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
HSIL Limited share price today is ₹385.50, down 0.28% on NSE/BSE as of 18 June 2026. HSIL Limited (HSIL) is a Small-cap company in the Medical Equipment & Supplies sector with a market capitalisation of ₹354.57 (Cr). The 52-week high for HSIL share price is ₹446.00 and the 52-week low is ₹91.00. At a P/E ratio of 34.23x, HSIL is currently trading below its industry average P/E of 47.87x. The company has a Return on Equity (ROE) of 13.58% and a debt-to-equity ratio of 0.43.
HSIL Limited Share Price Chart — NSE/BSE Historical Performance
HSIL Limited share price chart: 44.33% return over the past month. 52-week high ₹446.00, 52-week low ₹91.00.
HSIL Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹399.00 | ₹399.00 | ₹381.00 | ₹385.50 | 6.80K (Cr) | |
| ₹409.00 | ₹409.00 | ₹384.15 | ₹386.60 | 12.40K (Cr) | |
| ₹415.00 | ₹415.00 | ₹392.35 | ₹403.80 | 39.20K (Cr) | |
| ₹411.00 | ₹415.00 | ₹405.00 | ₹413.00 | 12.80K (Cr) | |
| ₹415.50 | ₹416.90 | ₹399.70 | ₹410.60 | 25.20K (Cr) | |
| ₹429.00 | ₹429.00 | ₹403.10 | ₹415.20 | 29.60K (Cr) | |
| ₹437.00 | ₹446.00 | ₹410.00 | ₹422.70 | 42.40K (Cr) | |
| ₹424.90 | ₹426.45 | ₹412.00 | ₹426.45 | 80.80K (Cr) | |
| ₹379.05 | ₹431.25 | ₹366.00 | ₹406.15 | 2.30L (Cr) | |
| ₹377.50 | ₹405.95 | ₹377.50 | ₹386.05 | 62.80K (Cr) |
HSIL Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹409.00 | ₹409.00 | ₹381.00 | ₹385.50 | -5.75% | |
| ₹304.90 | ₹446.00 | ₹288.00 | ₹403.80 | +32.44% | |
| ₹233.70 | ₹324.90 | ₹224.00 | ₹301.20 | +28.88% | |
| ₹281.00 | ₹289.00 | ₹215.00 | ₹217.50 | -22.60% | |
| ₹261.50 | ₹323.00 | ₹251.30 | ₹293.50 | +12.24% | |
| ₹299.00 | ₹304.15 | ₹256.50 | ₹266.25 | -10.95% | |
| ₹264.00 | ₹306.50 | ₹264.00 | ₹291.00 | +10.23% | |
| ₹295.00 | ₹300.00 | ₹247.50 | ₹259.00 | -12.20% | |
| ₹306.30 | ₹318.75 | ₹256.60 | ₹288.00 | -5.97% | |
| ₹297.80 | ₹367.10 | ₹296.00 | ₹312.50 | +4.94% | |
| ₹212.20 | ₹302.40 | ₹212.20 | ₹292.00 | +37.61% | |
| ₹93.02 | ₹215.00 | ₹91.68 | ₹208.08 | +123.69% |
AI Research Briefing
Powered by Gemini · 2026-04-10
HSIL is a micro-cap turnaround play with significant execution risk, dependent on government orders and localization efforts.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Hemant Surgical (HSIL) signed a C-ARM development and supply agreement with GBT Korea Co., Ltd. on April 2, 2026. On March 31, 2026, they also signed an SKD agreement with Sonomed Escalon USA to localize 100% ophthalmic ultrasound device manufacturing. CMSS purchase orders worth were received as of February 19.
CORE STORY (THE REAL GAME)
HSIL is being priced as a turnaround play in the medical equipment and supplies sector, shifting focus towards domestic manufacturing and strategic partnerships.
- CMSS purchase orders of ₹264.33 crore
- SKD agreement with Sonomed Escalon USA
- C-ARM development agreement with GBT Korea
- Successful execution of CMSS orders
- Ramp-up of localized ophthalmic ultrasound device manufacturing
- New product launches from C-ARM development
- Micro/SME cap - liquidity risk
- Execution risk in scaling up manufacturing
- Revenue concentration risk from government orders
DII increased stake significantly (Δ 9.7%) [cite: brief], while FII decreased stake (Δ -0.24%) [cite: brief]. Promoter holding stable at 58.9% [cite: brief].
India's medical equipment market is projected to reach USD 65.39 Billion by 2034, growing at a CAGR of 8.30% from 2026-2034.
CMSS purchase orders worth Rs.264.33 crore
Negative Free Cash Flow 5Y: ₹-31.31 Cr [cite: brief] - Profitability not converting to cash.
Focus on executing existing orders and scaling up domestic manufacturing. Success hinges on managing costs and diversifying revenue streams.
Primary Thesis Risk
Failure to execute on order book and localization strategy will crush the thesis.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
HSIL Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
HSIL Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of HSIL across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Excellent ROCE Performance (16.35%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 34.23 vs Industry: 47.87)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (70.13%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (31.49%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (13.69% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (74.11% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (58.90%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Weak Earnings Growth (-22.27% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-31.31 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
HSIL Limited vs Medical Equipment & Supplies Peers
Peer Comparison - Medical Equipment & Supplies
Compare HSIL Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
HSIL LimitedHSIL Limited...Selected✓ HSIL • 543916 | 61.2/100 | ₹385.50₹386 | ₹354.57₹354.57 | 34.23Average 34.2 Average | 13.58%Average 13.58% Average | 16.35%Good 16.35% Good | 0.43Excellent 0.4 Excellent | 74.11%Excellent 74.11% Excellent | 13.69%Good 13.69% Good | 0.00% |
Poly Medicure LtdPoly Medicure L... POLYMED • 531768 | 60.7/100 | ₹1330.30₹1330 | ₹19506.20₹19506.20 | 53.89Average 53.9 Average | 15.77%Good 15.77% Good | 20.08%Excellent 20.08% Excellent | 0.08Excellent 0.1 Excellent | 28.38%Excellent 28.38% Excellent | 19.44%Excellent 19.44% Excellent | 0.18% |
Fischer Medical Ventures LtdFischer Medical... FISCHER • 524743 | 31.7/100 | ₹37.46₹37 | ₹3162.93₹3162.93 | 157.52Average 157.5 Average | 0.70%Poor 0.70% Poor | 1.08%Poor 1.08% Poor | 0.08Excellent 0.1 Excellent | — — | — — | 0.01% |
Laxmi Dental LtdLaxmi Dental Lt... LAXMIDENTL • 544339 | 68.7/100 | ₹243.13₹243 | ₹1488.44₹1488.44 | 57.78Average 57.8 Average | 21.88%Excellent 21.88% Excellent | 19.20%Good 19.20% Good | 0.04Excellent 0.0 Excellent | 57.51%Excellent 57.51% Excellent | 9.81%Good 9.81% Good | 0.00% |
OSEL DEVICES LIMITEDOSEL DEVICES LI... OSELDEVICE • | 42.1/100 | ₹496.70₹497 | ₹1363.11₹1363.11 | 50.06Average 50.1 Average | 30.08%Excellent 30.08% Excellent | 31.14%Excellent 31.14% Excellent | 0.56Good 0.6 Good | — — | — — | 0.00% |
Tarsons Products LtdTarsons Product... TARSONS • 543399 | 13.8/100 | ₹214.98₹215 | ₹1224.98₹1224.98 | 59.58Average 59.6 Average | 4.75%Poor 4.75% Poor | 6.91%Poor 6.91% Poor | 0.63Good 0.6 Good | — — | — — | 0.00% |
60.3/100 | ₹173.00₹173 | ₹633.93₹633.93 | 25.77Average 25.8 Average | 36.78%Excellent 36.78% Excellent | 31.12%Excellent 31.12% Excellent | 0.53Good 0.5 Good | 90.06%Excellent 90.06% Excellent | 61.82%Excellent 61.82% Excellent | 0.00% | |
Prevest Denpro LtdPrevest Denpro ... PREVEST • 543363 | 68.5/100 | ₹408.00₹408 | ₹521.17₹521.17 | 26.18Average 26.2 Average | 18.74%Good 18.74% Good | 25.25%Excellent 25.25% Excellent | 0.00Excellent 0.0 Excellent | 29.49%Excellent 29.49% Excellent | 22.80%Excellent 22.80% Excellent | 0.23% |
47.7/100 | ₹187.00₹187 | ₹294.37₹294.37 | 32.71Average 32.7 Average | 13.56%Average 13.56% Average | 18.45%Good 18.45% Good | 0.01Excellent 0.0 Excellent | — — | — — | 0.00% | |
Nureca LtdNureca Ltd... NURECA • 543264 | 36/100 | ₹272.15₹272 | ₹292.61₹292.61 | 71.19Average 71.2 Average | -1.12%Poor -1.12% Poor | -0.90%Poor -0.90% Poor | 0.03Excellent 0.0 Excellent | — — | 1.98%Average 1.98% Average | 0.00% |
29.6/100 | ₹84.50₹85 | ₹189.41₹189.41 | 15.39Average 15.4 Average | 14.36%Average 14.36% Average | 16.60%Good 16.60% Good | 0.55Good 0.6 Good | — — | — — | 0.51% | |
Top Medical Equipment & Supplies Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Poly Medicure Ltd share price19506.20 Cr
- Fischer Medical Ventures Ltd share price3162.93 Cr
- Laxmi Dental Ltd share price1488.44 Cr
- OSEL DEVICES LIMITED share price1363.11 Cr
- Tarsons Products Ltd share price1224.98 Cr
HSIL Limited PE Ratio History
Historical price-to-earnings ratio for HSIL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹9.85 | ₹126.20 | 12.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
HSIL Limited Quarterly Performance
Latest quarterly metrics for HSIL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
31.49%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
70.13%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.69%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
74.11%
Compounded annual net profit growth over 5 years
HSIL Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for HSIL — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
HSIL Limited Financial Statements
Annual income statement, balance sheet and cash flow for HSIL Limited (HSIL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for HSIL Limited
About HSIL (HSIL Limited)
HSIL Limited is a dynamic player in the medical equipment and supplies sector, dedicated to providing high-quality solutions for healthcare professionals and patients alike. The co...mpany specializes in the comprehensive supply of essential medical products, from specialized surgical instruments to everyday medical consumables. With a strong commitment to innovation and adherence to stringent quality standards, HSIL Limited strives to meet the ever-evolving needs of the healthcare industry. This focus on excellence ensures that healthcare providers have access to reliable tools and supplies, empowering them to deliver the best possible care. HSIL Limited is constantly expanding its product portfolio and distribution network to reach a wider range of medical facilities and improve patient outcomes. The company's product range encompasses a wide variety of medical devices, diagnostic tools, and essential supplies. HSIL Limited provides a comprehensive selection of items crucial for effective diagnosis, treatment, and patient care, from sophisticated surgical instruments that demand precision to essential everyday supplies. The portfolio includes advanced diagnostic equipment, enabling healthcare professionals to detect and understand medical conditions accurately and efficiently. Understanding the critical importance of reliability in the medical field, HSIL Limited meticulously sources its products from trusted manufacturers, adhering to strict quality control protocols at every stage. This commitment to quality ensures the safety and efficacy of all products, instilling confidence in healthcare providers who rely on HSIL Limited's offerings. Beyond supplying medical equipment, HSIL Limited prioritizes exceptional customer service and builds lasting partnerships with healthcare providers. The company prides itself on understanding the unique needs of each customer and tailoring solutions accordingly. HSIL Limited's team of experienced professionals offers expert guidance and support, ensuring that clients can make informed decisions about the products they require. By focusing on building strong relationships, the company has earned a reputation for reliability and trustworthiness within the medical community. HSIL Limited is dedicated to contributing to the advancement of healthcare by providing innovative products and unparalleled customer support.
Company Details
Key Leadership
Latest News
HSIL Share Price: Frequently Asked Questions
What is the current share price of HSIL Limited?
HSIL Limited (HSIL) trades at ₹385.50 on NSE and BSE. Market cap ₹354.57 (Cr). Educational data only.
What is the P/E ratio of HSIL Limited?
HSIL Limited has a P/E of 34.23x vs industry average 47.87x.
What is the Bull Run score for HSIL Limited?
HSIL Limited has a Bull Run score of 61.2/100 based on 25+ financial parameters.
Does HSIL Limited pay dividends?
HSIL Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of HSIL Limited?
HSIL Limited has ROE of 13.58%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of HSIL Limited?
HSIL Limited has debt-to-equity of 0.43.
Is HSIL Limited a good investment?
Bull Run gives HSIL Limited a score of 61.2/100. This is not investment advice — consult a SEBI-registered advisor.